deltatrials
Completed OBSERVATIONAL NCT00577798

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

Cardiac MRI for Assessment of Cardiac Structure and Function Following Doxorubicin Based Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Sponsor: National Cancer Institute (NCI)

Updated 8 times since 2017 Last updated: Oct 10, 2023 Started: Jan 1, 2008 Primary completion: Mar 1, 2010 Completion: Feb 1, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Cardiac Toxicity and Chemotherapeutic Agent Toxicity, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Study Description(click to expand)

OBJECTIVES: * To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy. OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.

OBJECTIVES:

* To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy.

OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotUnknown Status~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2023 · 35 months · monthly snapshotCompleted~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed

  2. Sep 2024 — Present [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Dec 2023 — Jul 2024 [monthly]

    Completed

    Phase: NANone

  5. Jan 2021 — Dec 2023 [monthly]

    Completed NA

Show 3 earlier versions
  1. Jan 2019 — Jan 2021 [monthly]

    Completed NA

    Status: Unknown StatusCompleted

  2. Jun 2018 — Jan 2019 [monthly]

    Unknown Status NA

  3. Jan 2017 — Jun 2018 [monthly]

    Unknown Status NA

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Nebraska
Data source: University of Nebraska

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations